• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    It has been discovered that, in the case of amyotrophic lateral sclerosis, usually a lethal motoneuron disease, a large number of the immune system cells expressing receptors (Fc receptors) of immunoglobulins (IgC), preferably immunoglobulins of classes 1 and 3 (FcγRIII receptors for IgG1 and IgG3) can be found in the blood stream. Selective destruction or functional obstruction of these cells can be achieved in order to treat amyotrophic lateral sclerosis (ALS) with the following substances, or their preparations (in the form of intravenous applications or preparations), individually or in combination: a) antibodies, preferably monoclonal antibodies, which bind to FcγRIII receptors, inactivate said receptors or individual species of this receptor family or cause the destruction of cellular forms containing said receptors, and/or are coupled to other cytotoxic substances, b) soluble Fcγ receptors, preferably soluble FcγRIII receptors, which bind to immunoglobulins, preferably G immunoglobulins of under-class 1 (IgG1) and/or 3 (IgG3), c) the protein V which binds to immunoglobulin G, obtained from Gardnerella vaginalis, and d) antisense RNA molecules which bind specifically to MRNA sequences of Fcγ receptors, preferably to those of FcγRIII receptors.
    公开号:US20010009898A1
    申请号:US09/801,414
    申请日:2001-03-08
    公开日:2001-07-26
    发明作者:Walter Schubert
    申请人:Walter Schubert；
    IPC主号:A61K38-164
    专利说明:
    [0001] The invention relates to the use of substances having a well-directed, i.e. selective, effect on a certain receptor family (FcγR) or on those immune system cells with defined surface characteristics which express said receptor and whose presence—in examinations performed by the applicant—has been found to be specific, or its number specifically increased, in the case of amyotrophic lateral sclerosis. [0001]
    [0002] Amyotrophic lateral sclerosis (in the following referred to as ALS, its abbreviation) is a neurodegenerative disease of the human motoneuron system which usually takes a lethal course within 3 to 5 years, whose causes have not been determined etiologically and for which there is no, or no significant, therapy as yet. The progressive decay of nerve cells of the first and second motor neurons are the cause of an increasing paralysis of the voluntary muscles, eventually leading to a total walking inability and the increasing paralysis of the respiratory musculature. It has largely been proven that cellular and humoral (antibody-mediated) immunological processes play an important role, if yet unexplained in the individual case, in the pathogenesis of ALS. Worldwide, the prevalence of this disease is 4 in 100,000 and its incidence is 1 in 100,000 inhabitants. [0002]
    [0003] Numerous examination results seem to imply that immunological mechanisms are at play in the pathogenesis of amyotrophic lateral sclerosis. The following findings substantiate this assumption: Cytotoxic serum activity of ALS patients in neuronal cell cultures; serum immunoglobulin G (IgG) toxicity against spinal and cortical neurons as well as voltage-dependent calcium channel proteins; cytotoxicity of the cerebrospinal fluid of ALS patients against glutamate receptors; changes of the serum concentration of IgG isotypes; immune response of peripheral blood lymphocytes of ALS patients to isolated cell membranes; detection of invasive immune system cells in the motoneuron system of ALS patients Here, these cells seem to be involved in the motoneuron damaging mechanisms (the quotations of the individual above data can be found in: Westarp, M. E. et al., Neurosci. Lett. 173, 124-126, 1994). [0003]
    [0004] Although this data seems to imply a probable involvement of the cellular immune system in ALS, it has been impossible so far to detect definite quantitative or qualitative changes in the cellular immune system in the case of ALS. In particular, no ALS specific cell types have so far been found in the blood of ALS patients which would be identifiable by their molecular cell surface characteristics and clearly differ from immune cells of healthy experimentees or present in other neurological diseases. Nevertheless, countless therapies involving medication with a relatively broad effectivity as well as an undirected action were attempted in order to suppress or at least modulate immune functions. However, any such therapy attempt has remained without ascertained therapeutical success (cf. e.g. Brown, R. H. et al.: Arch. Neurol. 43, 383-384, 1986; and e.g. Dalakas, M. C. et al.: Arch. Neurol. 51, 861-864, 1994). A disadvantage of such approach is that these forms of therapy (blind or unaware of specific cell parameters with ALS) are not well-directed, i.e. they do not block or suppress exclusively those cell types which are specifically present, or present in significantly increased numbers, in ALS patients. [0004]
    [0005] Tests performed by the applicant have shown that the blood of ALS patients contains mononucleic cells of the immune system which are not found with any other neurological disease or in healthy persons (ALS specific immune cells, cf. Table 1). Contrary to the immune cell types so far observed to be present in increased numbers in ALS patients which are known as prior art (Schubert, W.; Neurosci. Lett. 198, 29-32, 1995), the cell types discovered according to the invention and listed in Table 1 are totally ALS specific. These cell types express receptors for immunoglobulins (Fcγ receptors), preferably for immunoglobulin G (IgG) of under-class 1 (IgG1) and 3 (IgG3) (in the following referred to as FcγRIII). The increased number, or the ALS specific occurrence, of said immune cells is an explanation of the hitherto unexplained reduction of IgG1 and IgG3 in the serum of patients diagnosed with ALS which was reported e.g. by Westarp et al. (Westarp, M. E. et al., Neurosci. Lett. 173, 124-126, 1994): FcγRIII receptors selectively bind to these immunoglobulins, i.e. a multiplication of cells expressing said receptors (as discovered in applicant's own studies) will result in increased binding to IgG1 and IgG3 and thus an IgG1-IgG3 clearance in this disease. In applicant's own studies, it has been found for the first time that these Fcγ receptor-positive cells exhibit a series of molecular activation characteristics on the cellular surface and, when cultured, will cause damage to, or even the destruction of, nerve cells. These cells are therefore directly involved in the pathomechanism of ALS and, as a cellular form, for the first time constitute a concrete target structure for a well-directed, i.e. specific, therapy with immunoactive substances. [0005]
    [0006] The present invention is therefore based on the discovery of Fcγ receptor positive, in particular FcγRIII positive, activated cellular forms in the blood stream which are ALS unspecific, or significantly increased in number in the case of ALS, and relates to a use of substances for the selective suppression, destruction or selective functional blocking of said cellular forms, or blocking or functional inactivation of Fcγ receptors, by infusion or injection of defined substances as specified in claim 1. [0006]
    [0007] Fcγ receptors have been known for quite some time in immunology. There are three different, yet related classes of human Fcγ receptors: FcγRI, FcγRII and FcγRIII. The amino acid sequences of the members of this receptor family as well as the genes coding for said receptors are known: FcγRI (Allen, J. M., Seed B.: Science 243, 378-380, 1989), FcγRII (Ravetch, J. V., Kinet, J.-P.: Annu. Rev. Immunol. 9, 457-492, 1991), FcγRIII (Ravetch, J. V., Perussia, B: J. Exp. Med. 170, 481-497, 1989). Most subtypes of these three receptor classes are anchored in the cell membrane of certain immune cells. However, all three classes also contain soluble receptor proteins, i.e. proteins not anchored in the cell membrane, which are naturally-released by immune cells. The mechanisms are different, however. Soluble FcγRI receptors are generated by a stop codon in the extracellular domain. Soluble FcγRII receptors are generated by alternative RNA splicing, and soluble FcγRIII receptors are generated by proteolytic splitting of the receptor anchored in the cell membrane (cf. summarizing survey in: Jan, G. J. et al.: Immunology Today, 14, 215-221, 1993). [0007]
    [0008] Said Fcγ receptors are particularly relevant for a number of important immunologic functions. All these functions are based on the fact that Fcγ receptors specifically bind to G immunoglobulins. The binding of such immunoglobulins to Fcγ receptors stimulates or triggers a variety of different cellular activities: Phagocytosis, endocytosis, antibody-dependent cell-mediated cytotoxicity, the release of soluble, inflammation-promoting factors (mediators) as well as the increase of antigen presenting mechanisms. G immunoglobulins bind to Fcγ receptors via their Fc parts. If G immunoglobulins for example bind to Fcγ receptors anchored on the surface of certain immune cells in this manner, said immune cells will then be capable of binding very specifically to antigen-bearing target cells and destroying them. These mechanisms probably play an important pathogenetic part in numerous so called auto immune diseases. In some cases it has been possible to show that blocking or functionally inactivating said mechanisms largely prevents the disease specific destruction of target cells. One example hereof is a rare form of an auto immune disease in humans, the so called acute immuno-thrombocytopenic purpura, in which an Fcγ receptor-mediated cytotoxic activity of the immune system against blood platelets results in an acute diminution of said platelets (thrombocytes) in the blood of affected patients. In this case, it has been possible to show that the infusion of soluble Fcγ receptor fragments results in a clear recovery from the symptoms and the cellular signs of the disease (Debre et al.: Lancet, 342, 945-948, 1993). [0008]
    [0009] In the case of ALS, however, an immunological pathomechanism based on the activity of Fcγ receptors has not been known so far. Also, a form of therapy directed at specifically inactivating or blocking such mechanism has not been developed or conducted. [0009]
    [0010] Now, however, the existence of accordingly specific cellular forms and such mechanisms has been confirmed by the results of examinations conducted by the applicant. [0010]
    [0011] In detail, it has been found [0011]
    [0012] that the blood of ALS patients contains mononucleic cells bearing Fcγ receptors on their cellular surfaces, additionally or simultaneously bearing a different number of various other receptor proteins which exhibit an unusual form of cellular surface activation. The surface receptors variably co-expressed together with Fcγ receptors, above all FcγRIII receptors, are individually designated in Table 1. The abbreviations (CD) used therein are in keeping with the international nomenclature (cf. Barcley, A. N. et al.; The leucocyte antigen facts book. Academic press. London. 1993). This special combination of Fcγ receptors (e.g. CD16) with other receptor proteins indicated in Table 1 is ALS specific since it could not be detected in healthy persons or with other neurological control diseases or other immunological, non-neurological diseases; [0012]
    [0013] that these cells, after being isolated from the blood of ALS patients, could be cultivated in cell culture media (the standard protocols on which this was based are described in Lindl, T., Bauer, J.: Zell- und Gewebekultur, published by G. Fischer Verlag, Stuttgart, 1987), [0013]
    [0014] that said cells, after enrichment and in co-cultivation with nerve cells and serum of ALS patients, develop a cytotoxic activity resulting in the destruction of the nerve cells, p[0014] 1 that it is possible to block said cytotoxic activity by the addition of various soluble factors:
    [0015] a) by monoclonal antibodies against Fcγ receptors at a concentration of between 20 and 100 μmol, [0015]
    [0016] b) by soluble Fcγ receptors at a concentration of between 10 and 60 μmol, [0016]
    [0017] c) by anti-sense messenger ribonucleic acid species (MRNA) which are complementary to Fcγ receptor-specific mRNA sequences (e.g. 20 μmol of a no. 23 anti-sense oligonucleotide, derived from EMBL/gene bank FcγRIII sequence X16863), [0017]
    [0018] d) by protein V isolated from [0018] Gardnerella vaginalis (EP: 0595997) at concentrations of between 150 to 170 μmol in the simultaneous presence of serum from ALS patients.
    [0019] Consequently, the solution according to the invention is the blocking of the Fcγ receptor-mediated cytotoxic activity of the ALS-specific Fcγ receptor-positive immune cells, or the blocking or the inactivation of Fcγ receptors, or the destruction thereof, by the administration of the abovementioned substances, so as to prevent the direct or indirect pathological effects of these cells or the Fcγ receptors on the motoneuron system. [0019]
    [0020] Said substances will therefore be applied in the respective therapeutic dosage and after a toleration test in bolus (see the examples). Approximate values are the following concentrations, for example: for FcγR specific antibodies (10 to 1,000 mg/weight kg, once or twice a day i.v.) , for Fcγreceptor specific anti-sense RNA (10 to 20 mg/kg), for soluble Fcγ receptors (10 to 1,000 mg/kg), for protein V (10 to 1,000 mg/kg). [0020]
    [0021] However, an exact therapeutic dose can only be decided on with respect to the individual case concerned It depends, amongst other things, on the response of the Fcγ receptor-positive cells to the administration of the substances as indicated in claim 1 and on the individual toleration which may be determined by single bolus administrations (see example 1) Such response may e.g. be established by the determination of the number of such cellular forms in the blood or by in-vitro cytotoxicity assays. If necessary, the dosage and the distribution of the daily dosis may have to be modified according to the individual case concerned. [0021]
    [0022] The solution according to the invention has the following advantages: [0022]
    [0023] 1. In contrast to all other forms of immunosuppressive or immunomodulating therapy performed so far which were substantially unspecific and affected the entire immune system, the form of therapy disclosed herein constitutes a well-directed form of therapy, i.e. directed at ALS specific forms of immune cells. [0023]
    [0024] 2 Based on the knowledge, according to the invention, of the ALS specific surface characteristics, i.e. the combinatorial receptor patterns of these cells (see Table 1), it is possible to ascertain before each therapy whether these cells are present at all, or, after their isolation and in-vitro testing, to determine whether they exhibit any cytotoxic, in particular neurotoxic, activity. [0024]
    [0025] 3 Based on the knowledge, according to the invention, of the cell surface characteristics of these cells, the therapeutical success can not only be determined clinically, but also on a cellular level, with the therapy according to claim 1 in full progress, by the examination of blood samples for a therapy-related decrease in the number, or even a total elimination, of the Fcγ receptor-positive cellular forms from the blood stream. [0025]
    [0026] 4. Based on the findings of above step 3, the dosage of the administered substances may be adapted accordingly, i.e. increased or decreased, depending on whether or not there is a response of the Fcγ receptor-positive cellular forms. [0026]
    [0027] 5. Since the knowledge, according to the invention, of the cell surface characteristics of the ALS specific cellular forms for the first time constitutes a disease-specific cell parameter for ALS, it is possible to correlate the clinical course of the disease precisely with this parameter so that, even after a discontinuation of the therapy in accordance with the inventive muse of Fcγ receptor-specific substances, a potential re-increase of the Fcγ receptor-positive cells will allow exact determination of the time for a further therapy cycle. [0027]
    [0028] The solution according to the invention, including the way it works, is described in more detail hereinafter with reference to an embodiment [0028] Patient: X1 Diagnosis: ALS, bulbous type Substance: soluble Fcγ receptor preparations, 50 kDa, from E. coli (fusion proteins from E. coli) Mode of application: intravenous Therapeutical scheme: toleration test with 10 to 1,000 mg/kg in bolus i.v., subsequently 150 mg/weight kg daily, over a period of 5 days
    [0029] [0029] TABLE 1 ALS Control CD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 n CD16 + + + + + + + + + + + + + + + + + + CD2 + + + + + − − − − − − − − − − − − − CD3 + + + + + + + + + + + + + + + + + + CD4 + + + + + + + − + + + + + + + − − + CD8 − + − − − − − − − − − − − − − − − − CD56 − − + + + + + + + + + − − − − + + − CD57 + − + − − − − − − − − − − − − − − − CD26 − + − − − − − − − − − − − − − − − − CD38 + − + + + + + + + + + + + + + + + + CD71 − + − − − − − − − − − − − − − − − − HLA−DR + − + + + + + + + + − + + − − − − − HLA−DQ − − − − − − − − − − − − − − − − − − CD11b + − − − − + + − − − − + − + + − − − CD45Ra − + − − − − − − − − − − − − − − − − CD7 + − + − − + − + − − − − + − − − − − CD62L + − + + − + + + + − − + + + − − + + CD36 − + − − − − − − − − − − − − − − − CD19 − − − − − − − − − − − − − − − −
    权利要求:
    Claims (1)
    [1" id="US-20010009898-A1-CLM-00001] 1. The use of Protein V which binds to immunoglobulin G, obtained from Gardnerella vaginalis or preparations thereof, individually or in combination, for the treatment of amyotrophic lateral sclerosis (ALS).
    类似技术:
    公开号 | 公开日 | 专利标题
    US6638515B2|2003-10-28|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V
    Hale et al.1988|Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H
    Wofsy et al.1987|Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
    Hellström et al.1977|Specific blocking factors—are they important?
    JP4148537B2|2008-09-10|CD40CR receptor and its ligand
    JP5215723B2|2013-06-19|Use of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
    Daëron et al.1980|Mast cell membrane antigens and Fc receptors in anaphylaxis: II. Functionally distinct receptors for IgG and for IgE on mouse mast cells
    Kedar et al.1974|Comparative studies of immunoglobulin receptors and antibody-dependent cell cytotoxicity | in rat lymphoid organs
    JP4053596B2|2008-02-27|Antibody production and medical use involving antibodies
    US6638506B1|2003-10-28|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using antibodies to FcγRIII
    Nisonoff et al.1964|Immunochemistry
    EA013517B1|2010-06-30|Use of polyclonal anti-hiv goat serum as a therapeutic agent for the preparation of a medicament
    JP4263391B2|2009-05-13|Use of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
    De Gast et al.1973|The human immune response to α‐haemocyanin of Helix pomatia
    ES2234038T3|2005-06-16|USE OF SUBSTANCES WITH IMMUNOMODULATOR EFFECT FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS.
    Armerding et al.1975|Activation of T and B Lymphocytes in Vitro: IV. Regulatory Influence on Specific T Cell Functions by a Thymus Extract Factor
    Lebar et al.1974|Studies on Auto-Immune Encephalomyelitis in the Guinea Pig
    Pollack et al.1975|Evidence for two factors in sera of tumor‐immunized mice which induce specific lymphoid cell‐dependent cytotoxicity: IgG2 and a rapidly appearing factor not associated with IgG or IgM
    Beauvais et al.1990|Bimodal IgG4-mediated human basophil activation. Role of eosinophils.
    JPH10505356A|1998-05-26|Compositions and methods for administration to humans, peptides capable of down-regulating an antigen-specific immune response
    US20040247589A1|2004-12-09|Anti-tumor activity from reptile serum
    US6534057B2|2003-03-18|Method increasing the delayed-type hypersensitivity response by infusing LFA-1-specific antibodies
    WO1999047166A1|1999-09-23|IMMUNOMODULATORY FRAGMENTS OF POLYCLONAL ANTILYMPHOCYTE GLOBULINS | AND USES THEREOF
    Greenaway et al.1994|A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia
    AU599037B2|1990-07-12|Treatment of chronic inflammatory disease
    同族专利:
    公开号 | 公开日
    US20010055592A1|2001-12-27|
    US6649165B2|2003-11-18|
    US6638515B2|2003-10-28|
    US20040053846A1|2004-03-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP1443965A1|2001-11-13|2004-08-11|The University Of Liverpool|Treatment of inflammatory conditions|
    EP3419664A4|2016-02-25|2019-08-28|B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University|Composition and method for treating amyotrophic lateral sclerosis|DE19723690A1|1996-06-05|1998-03-26|Schubert Walter Dr Md|Use of Fc-gamma receptor antibodies|
    US6638506B1|1997-06-05|2003-10-28|Walter Schubert|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using antibodies to FcγRIII|
    US6638515B2|1999-09-07|2003-10-28|Walter Schubert|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V|US6638515B2|1999-09-07|2003-10-28|Walter Schubert|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V|
    US8188231B2|2002-09-27|2012-05-29|Xencor, Inc.|Optimized FC variants|
    US8388955B2|2003-03-03|2013-03-05|Xencor, Inc.|Fc variants|
    US9051373B2|2003-05-02|2015-06-09|Xencor, Inc.|Optimized Fc variants|
    US20090010920A1|2003-03-03|2009-01-08|Xencor, Inc.|Fc Variants Having Decreased Affinity for FcyRIIb|
    US8084582B2|2003-03-03|2011-12-27|Xencor, Inc.|Optimized anti-CD20 monoclonal antibodies having Fc variants|
    US7317091B2|2002-03-01|2008-01-08|Xencor, Inc.|Optimized Fc variants|
    US20060235208A1|2002-09-27|2006-10-19|Xencor, Inc.|Fc variants with optimized properties|
    US8093357B2|2002-03-01|2012-01-10|Xencor, Inc.|Optimized Fc variants and methods for their generation|
    US20080254027A1|2002-03-01|2008-10-16|Bernett Matthew J|Optimized CD5 antibodies and methods of using the same|
    US20070275460A1|2003-03-03|2007-11-29|Xencor.Inc.|Fc Variants With Optimized Fc Receptor Binding Properties|
    US9714282B2|2003-09-26|2017-07-25|Xencor, Inc.|Optimized Fc variants and methods for their generation|
    US8101720B2|2004-10-21|2012-01-24|Xencor, Inc.|Immunoglobulin insertions, deletions and substitutions|
    DK1931709T3|2005-10-03|2017-03-13|Xencor Inc|FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES|
    US20040132101A1|2002-09-27|2004-07-08|Xencor|Optimized Fc variants and methods for their generation|
    WO2005077981A2|2003-12-22|2005-08-25|Xencor, Inc.|Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES|
    AU2005227326B2|2004-03-24|2009-12-03|Xencor, Inc.|Immunoglobulin variants outside the Fc region|
    US20060074225A1|2004-09-14|2006-04-06|Xencor, Inc.|Monomeric immunoglobulin Fc domains|
    US8546543B2|2004-11-12|2013-10-01|Xencor, Inc.|Fc variants that extend antibody half-life|
    US8367805B2|2004-11-12|2013-02-05|Xencor, Inc.|Fc variants with altered binding to FcRn|
    EP2325206B1|2004-11-12|2014-03-19|Xencor, Inc.|Fc variants with altered binding to fcrn|
    US8802820B2|2004-11-12|2014-08-12|Xencor, Inc.|Fc variants with altered binding to FcRn|
    CA2595169A1|2005-01-12|2006-07-20|Xencor, Inc.|Antibodies and fc fusion proteins with altered immunogenicity|
    EP1951757B1|2005-10-06|2014-05-14|Xencor, Inc.|Optimized anti-cd30 antibodies|
    DE102006063050B8|2006-03-13|2019-12-05|ToposNomos Ltd.|Device and method for identifying and identifying target structures|
    DE102006011467B4|2006-03-13|2019-08-29|ToposNomos Ltd.|Device and method for identifying and identifying target structures|
    PT2383297E|2006-08-14|2013-04-15|Xencor Inc|Optimized antibodies that target cd19|
    AU2007299843B2|2006-09-18|2012-03-08|Xencor, Inc|Optimized antibodies that target HM1.24|
    US7580304B2|2007-06-15|2009-08-25|United Memories, Inc.|Multiple bus charge sharing|
    US8362210B2|2010-01-19|2013-01-29|Xencor, Inc.|Antibody variants with enhanced complement activity|
    法律状态:
    2004-10-19| CC| Certificate of correction|
    2005-07-05| AS| Assignment|Owner name: MELTEC MULTI-EPITOPE-LIGAND-TECHNOLOGIES GMBH, GER Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHUBERT, WALTER;REEL/FRAME:016460/0890 Effective date: 20040315 |
    2005-07-06| AS| Assignment|Owner name: MPB MELTEC PATENT-UND BETEILIGUNGSGESELLSCHAFT MBH Free format text: CHANGE OF NAME;ASSIGNOR:MELTEC MULTI-EPITOPE-LIGAND-TECHNOLOGIES GMBH;REEL/FRAME:016480/0035 Effective date: 20040729 |
    2007-05-16| REMI| Maintenance fee reminder mailed|
    2007-10-28| LAPS| Lapse for failure to pay maintenance fees|
    2007-11-26| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2007-12-18| FP| Expired due to failure to pay maintenance fee|Effective date: 20071028 |
    优先权:
    申请号 | 申请日 | 专利标题
    US09/367,011|US6638506B1|1997-06-05|1997-12-10|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using antibodies to FcγRIII|
    US09/801,414|US6638515B2|1999-09-07|2001-03-08|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V|US09/801,414| US6638515B2|1999-09-07|2001-03-08|Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V|
    [返回顶部]